PharmaFocus Today – Page 5 – media

MRI scans reveal why young women face higher risk for eating disorders

Breakthrough MRI scans reveal hidden hypothalamic changes in young women, shedding light on the biological roots of anorexia and obesity, and paving the way for targeted treatments. A recent editorial feature published in the American Journal of Clinical Nutrition discusses the use of a novel imaging technique to investigate how certain structural features of the hypothalamus affect eating behaviors. A new approach to studying the hypothalamus Women are more likely to develop eating disorders like anorexia nervosa than men, particularly during puberty. Despite this disproportional occurrence, few studies have investigated the role of the female brain in neuroscience and psychiatry. The hypothalamus is a small, heterogeneous brain structure in the diencephalon that regulates homeostatic and hedonic functions involved in feeding behaviors. Current imaging techniques are limited in their ability to capture nuclei subsegmentation within the hypothalamus. As a result, most studies investigating the role of the hypothalamus have been conducted ...
- Source: drugdu
- 59
- May 28, 2025
Guangdong Province launches quantity based procurement, including 170 drugs and 248 product specifications | early reference materials for pharmaceuticals

No.1 Guangdong Province launches quantity based procurement, including 170 drugs and 248 product specifications Recently, the Guangdong Provincial Drug Trading Center issued a notice stating that 22 provinces (including the Corps) within the alliance will continue to purchase 170 varieties and 248 specifications of drugs, except for those that overlap with national procurement (including national joint procurement), national medical insurance negotiated drugs (including bidding drugs), and national basic medical insurance drug catalogs. This procurement has cancelled A/B purchase orders and opted for group bidding. Comment: Guangdong Province has launched a 22 province alliance drug procurement, involving 170 varieties. The A/B purchase orders have been cancelled and grouped for bidding, which may promote drug price reduction and industry integration. NO.2 Shandong Heda: The US Department of Commerce has preliminarily ruled that the anti-dumping tax rate obtained by the company’s wholly-owned subsidiary is 172.24% On the evening of May 26th, Shandong ...
- Source: drugdu
- 51
- May 28, 2025
21 Health News Daily | Yuheng Pharmaceutical and Xinghe Pharmaceutical signed a promotion agreement; Shareholders of Chengdu Pioneer and Aojing Medical reduce their holdings

Policy Tendence The National Medical Products Administration issued a document requiring the implementation of the “Quality Management Standards for Medical Device Network Sales” On May 26th, the National Medical Products Administration announced that the “Quality Management Standards for Online Sales of Medical Devices” (hereinafter referred to as the “Standards”) will officially come into effect on October 1, 2025. Drug regulatory departments at all levels should guide online sales operators and e-commerce platform operators to actively carry out internal training and assessment, focusing on the comprehensiveness of the quality management system coverage of online sales operators, the standardization of product information display, the completeness of online sales related records, as well as the establishment of full process quality management records, verification and updating of network operator files, and the monitoring and risk consultation of medical device quality and safety risks within the platform. Enterprises should conduct key self inspections. Medical device ...
- Source: drugdu
- 58
- May 28, 2025
Kexing Biotech’s wholly-owned subsidiary is approved to conduct clinical trials of GB18 injection

On May 26, Kexing Pharmaceuticals issued an announcement that recently, the company’s wholly-owned subsidiary Shenzhen Kexing Pharmaceutical Co., Ltd. received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration, approving it to conduct clinical trials of “GB18 Injection”. The injection is an innovative drug targeting GDF15, designed to treat tumor cachexia. Preclinical data show that GB18 injection has obvious differentiated advantages, can effectively reverse weight loss caused by tumor cachexia, and improve muscle and fat quality. In the first quarter of 2025, Kexing Biotech achieved revenue of 354 million yuan and net profit attributable to shareholders of the parent company of 25.58 million yuan. https://finance.eastmoney.com/a/202505263414629127.html
- Source: drugdu
- 52
- May 28, 2025
Angel Yeast plans to invest 230 million yuan to develop serum-free cell culture medium technology

May 26, Angel Yeast issued an announcement that it plans to implement a key technology research project for serum-free cell culture medium. The total investment of the project is estimated at RMB 230 million, aiming to promote the development of the company’s biotechnology and meet the needs of antibodies, vaccines and recombinant proteins. Other biological products The project will explore the existing synthetic biology The pilot platform has been upgraded and renovated to add a serum-free cell culture medium preparation platform and a core raw material refining and purification platform. It is expected to produce 200 tons of dry powder serum-free cell culture medium and 100,000 liters of liquid serum-free cell culture medium annually. The project construction period is expected to be 30 months, and it is scheduled to be put into production in 2027. The funds will come from the company’s own funds. In the first quarter of 2025, ...
- Source: drugdu
- 52
- May 28, 2025
A new starting point for Hengrui

Hengrui Medicine was founded in 1970. Its predecessor was a small pharmaceutical factory in Lianyungang, Jiangsu (Lianyungang Pharmaceutical Factory). In 1982, Sun Piaoyang joined Lianyungang Pharmaceutical Factory and took office as the new factory director in 1990. Under his leadership, Hengrui Medicine gradually grew from generic drugs to innovative drugs, and became a leader in China’s pharmaceutical field. In 2020, Hengrui Medicine’s market value exceeded 600 billion yuan, driven by innovative products such as carrelizumab. However, with the advancement of national centralized procurement and medical insurance negotiations, Hengrui Medicine’s performance faces severe challenges, and its revenue and net profit have not yet returned to the highs of Q4 2020. The revenue of the generic drug business has shrunk sharply in the past few years, bringing Hengrui Medicine’s performance into its darkest moment, with revenue falling from 27.73 billion yuan in 2020 to 22.82 billion yuan in 2023. In 2024, although ...
- Source: drugdu
- 51
- May 28, 2025
Adjustment of tariff policy on EU

According to a news flash from Xinhua News Agency, US President Trump said on the 25th that he agreed to extend the deadline for imposing a 50% tariff on EU goods to July 9. It is reported that the United States had previously proposed a new “reciprocal tariff” measure in April, wielding the tariff stick at several major trading partners including the European Union, but it also gave a 90-day “deferment period”, which was originally due to end on July 9. However, on May 23rd local time, Trump announced that due to the slow progress of the EU in negotiations and its unfair targeting of US companies through litigation and regulatory means, he would impose a 50% tariff on EU goods from June 1st. This news instantly caused widespread shock in the market, and all parties paid attention to the subsequent development of the situation. Just when the situation seemed ...
- Source: drugdu
- 43
- May 28, 2025
Health Daily | Rongchang Biotechnology raises HKD 800 million through placement financing; Biotech adjusts development strategy and terminates a research project

Policy Tendence From January to April 2025, the amount of mutual assistance in employee medical insurance personal accounts was 17.792 billion yuan On May 22nd, the National Healthcare Security Administration announced that the mutual assistance of employee medical insurance personal accounts can be achieved through instant calling of the bound person’s personal account, medical insurance wallet transfer, and other methods. From January to April 2025, the personal accounts of employees’ medical insurance assisted 133 million people, with a total amount of 17.792 billion yuan. From the perspective of mutual aid regions, within the same overall planning area (usually the same city), there were 121 million mutual aid visits and a total mutual aid amount of 15.844 billion yuan; Within the province, there were 11.0188 million cross regional mutual aid visits, with a total amount of 1.914 billion yuan. From the perspective of mutual aid purposes, 15.857 billion yuan was used ...
- Source: drugdu
- 58
- May 26, 2025
Tonghua Dongbao plans to transfer a portion of its shares in Tebao Biotechnology through an agreement; Lizhu Group plans to acquire a portion of the equity of IMP, a Vietnamese pharmaceutical company

NO.1 Biotech adjusts BAT3306 development strategy Biotech announced that after a careful evaluation of the company’s drug supervision and management policies and other factors, it plans to adjust the development strategy of BAT3306 (pembrolizumab) and terminate the ongoing BAT3306-002 study on BAT3306 (an evaluation of the combination of BAT3306 and chemotherapy with Credesia) ® A multicenter, randomized, double-blind phase I/III study on the pharmacokinetics, efficacy, and safety of combination chemotherapy in patients with stage IV non-small cell lung cancer. Comment: Biotech’s adjustment of this research and development strategy is based on the fact that the necessity of efficacy comparison studies has greatly decreased when the European and American drug regulatory authorities approve the marketing application of biosimilar products. However, Biotech stated in the announcement that it will carefully evaluate and make a decision on whether to continue advancing the BAT3306 project in the future, reflecting the current fierce competition in ...
- Source: drugdu
- 61
- May 26, 2025
FDA Approves Roche’s Susvimo for Diabetic Retinopathy

The FDA has approved Roche’s Susvimo (ranibizumab injection) 100 mg/mL for treating patients with diabetic retinopathy (DR). The regulatory action makes Susvimo the first and only FDA-approved continuous delivery therapy for DR. What Makes Susvimo a Breakthrough in Diabetic Retinopathy Care? The therapy offers a significant advancement with just one refill every nine months, providing sustained vision benefits in patients who have previously responded to at least two anti-VEGF injections, according to Roche. Approval was based on positive one-year data from the Phase III Pavilion study, which demonstrated superior improvement on the Diabetic Retinopathy Severity Scale (DRSS) and a reduced need for supplemental treatment compared to standard care.1 “The approval of Susvimo for diabetic retinopathy expands treatment options for patients, offering predictable and immediate durability after implantation with only one treatment every nine months,” said Levi Garraway, MD, PhD, chief medical officer, head, global product development, Roche, in a press ...
- Source: drugdu
- 49
- May 26, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.